异甘草酸镁与复方甘草酸苷对肝病疗效的荟萃分析

Therapeutic Effects Comparison on Magnesium Isoglycyrrhizinate and Compound Glycyrrhizin in Treatment of Patients With Liver Disease:A Meta-analysis

目的评价异甘草酸镁与复方甘草酸苷治疗肝病的疗效与安全性比较。方法检索PUBMED、Cochrane Library、万方、维普和CNKI中国期刊全文数据库2015年7月前已发表的关于异甘草酸镁与复方甘草酸苷治疗肝病的随机临床对照试验研究。利用Revman 5.0进行荟萃分析。结果7项临床试验(共962例)纳入荟萃分析。试验组总体有效率89.65%(433/483),差异有统计学意义。试验组及对照组ALT、AST、TBIL改善率具有统计学意义。药物不良反应发生率有明显差异。结论异甘草酸镁注射液能改善肝病患者临床症状,促进肝功能的恢复,对TBIL改善效果更明显,减少不良反应发生率。

Objective To evaluate the efficacy and safety of magnesium isoglycyrrhizinate and compound glycyrrhizin in the treatment of liver diseases.Methods Correlated randomized controlled clinical trials comparing on magnesium isoglycyrrhizinate and compound glycyrrhizin in the treatment of liver disease was searched in PUBMED,Cochrane Library,WANFANG STATA,VIP and National Knowledge Infrastructure.Revman 5.0 software was used for the meta-analysis.Results Seven RCTs(962 in total)were included in the meta-analysis.The total effective rate of the experimental group was 89.65%(433/483),and the difference was statistically significant.The improvement rates of ALT,AST and TBIL in the experimental group and the control group were statistically significant.There were significant differences in the incidence of adverse drug reactions.Conclusion Magnesium isoglycyrrhizinate therapy can improve the clinical symptoms of patients with liver disease,and promote liver function recovery,with the lower adverse reaction rate.